CIK 0001822462 · Non-accelerated filer<br>Smaller reporting company
Foghorn Therapeutics Inc.
Sign in to watch- Ticker
- FHTX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- Phone
- 617-586-3100
- Business address
- 500 TECHNOLOGY SQUARE, SUITE 700, CAMBRIDGE, MA, 02139
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2022-06-21 | Cole Douglas G. Director | Grant or award · Stock Options (Right to buy) | +16,000 | 16,000 | ||
| 2022-06-21 | SMITH IAN F Director | Grant or award · Stock Options (Right to buy) | +16,000 | 16,000 | ||
| 2022-06-21 | KADOCH CIGALL Director | Grant or award · Stock Options (Right to buy) | +16,000 | 16,000 | ||
| 2022-06-21 | GILL SIMBA Director | Grant or award · Stock Options (Right to buy) | +16,000 | 16,000 | ||
| 2022-06-21 | Koppel Adam Director | Grant or award · Stock Options (Right to buy) | +16,000 | 16,000 | ||
| 2022-05-25 | Bellon Steven F. Chief Scientific Officer | Option exercise | +675 | $0.73 | $493 | 116,382 |
| 2022-05-25 | Bellon Steven F. Chief Scientific Officer | Option exercise | +3,717 | $3.72 | $14K | 120,099 |
| 2022-05-25 | Bellon Steven F. Chief Scientific Officer | Option exercise · Stock Options (Right to buy) | −675 | 0 | ||
| 2022-05-25 | Bellon Steven F. Chief Scientific Officer | Option exercise · Stock Options (Right to buy) | −3,717 | 5,574 | ||
| 2022-02-10 | GOTTSCHALK ADRIAN Chief Executive Officer | Gift | −123,479 | 23,000 | ||
| 2022-02-10 | GOTTSCHALK ADRIAN Chief Executive Officer | Gift | +123,479 | 448,704 | ||
| 2022-01-26 | Agresta Samuel Chief Medical Officer | Grant or award · Stock Option (right to buy) | +125,000 | 125,000 | ||
| 2022-01-26 | Bellon Steven F. Chief Scientific Officer | Grant or award · Stock Option (right to buy) | +150,000 | 150,000 | ||
| 2022-01-26 | LaCascia Michael Chief Legal Officer | Grant or award · Stock Option (right to buy) | +135,000 | 135,000 | ||
| 2022-01-26 | Reine Allan Chief Financial Officer | Grant or award · Stock Option (right to buy) | +135,000 | 135,000 | ||
| 2022-01-26 | GOTTSCHALK ADRIAN Chief Executive Officer | Grant or award · Stock Option (right to buy) | +440,000 | 440,000 | ||
| 2021-12-14 | KADOCH CIGALL Director | Gift | −333,333 | 295,000 | ||
| 2021-12-09 | DECICCO CARL Chief Scientific Officer | Option exercise | +104,310 | $3.72 | $388K | 362,707 |
| 2021-12-09 | DECICCO CARL Chief Scientific Officer | Option exercise · Stock Options (Right to buy) | −76,892 | 186,571 | ||
| 2021-12-09 | DECICCO CARL Chief Scientific Officer | Option exercise · Stock Options (Right to buy) | −27,418 | 34,273 |
Page 7 of 9 · 177 trades